Physician profile
Stephen Babic
NPI 1750491064
$5,910.62
in general payments reported to CMS, 2019-2025
30 companies · $375 in 2025
The $375 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,255 · 2020: $443 · 2021: $1,103 · 2022: $989 · 2023: $722 · 2024: $1,023 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,119.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,007.23 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $874.30 | 2020-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $523.36 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $475.71 | 2021-2023 | Farxiga |
| Pfizer INC. | $416.58 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $407.84 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $383.81 | 2019-2025 | |
| Amgen INC. | $347.35 | 2019-2021 | |
| Heartflow, INC. | $278.56 | 2022-2023 | Ffrct |
| Silk Road Medical, INC. | $186.86 | 2022 | |
| Abbott Laboratories | $185.75 | 2020-2024 | Epic |
| La Jolla Pharmaceutical Company | $126.53 | 2019 | |
| Medtronic Vascular, INC. | $113.28 | 2019 | |
| Atricure, INC. | $111.87 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $84.99 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $50.16 | 2022-2024 | Watchman Flx |
| Cvrx, INC. | $49.86 | 2023-2024 | Barostim Neo System |
| Agepha Pharma Fz LLC | $43.68 | 2024-2025 | Lodoco |
| Viatris Specialty LLC | $34.92 | 2025 | Yupelri |
| Alnylam Pharmaceuticals INC. | $27.82 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $24.00 | 2023 | Inpefa |
| Cleerly, INC. | $21.99 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Kiniksa Pharmaceuticals International, Plc | $20.10 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.63 | 2021 | |
| Amryt Pharma Holdings LTD | $18.33 | 2021 | |
| Merck Sharp & Dohme LLC | $15.85 | 2023 | Verquvo |
| Scpharmaceuticals INC. | $15.85 | 2023 | |
| Esperion Therapeutics, INC. | $15.80 | 2024 | Nexletol |
| Cashflow Solutions, LLC | $15.61 | 2024 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Bardy Diagnostics, INC. | $13.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Babic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.